A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
NCT06113328
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
169
Enrollment
INDUSTRY
Sponsor class
Stopped
Business Reasons
Conditions
Non-segmental Vitiligo
Interventions
BIOLOGICAL:
MK-6194
DRUG:
Placebo
Sponsor
Merck Sharp & Dohme LLC